COVID-19 At-Home Test granted FDA Emergency Use Authorization to expand access to rapid self-testing solutions in the United States – Roche

Roche has announced that the FDA has granted Emergency Use Authorization (EUA) for its COVID-19 At-Home Test. The test uses a simple anterior nasal swab sample that can be conveniently self-collected and self-tested by individuals aged 14 years and older, and by an adult for children aged 2-13 years old. The test is able to produce accurate, reliable and quick […]

Supermeres’ may carry clues to cancer, Alzheimer’s disease and COVID-19

Researchers at Vanderbilt University Medical Center have discovered a nanoparticle released from cells, called a “supermere,” which contains enzymes, proteins and RNA associated with multiple cancers, cardiovascular disease, Alzheimer’s disease and even COVID-19. The discovery, reported in Nature Cell Biology, is a significant advance in understanding the role extracellular vesicles and nanoparticles play in shuttling important chemical “messages” between cells, both […]

European Commission approves Ronapreve to treat of non-hospitalized patients (outpatients) with confirmed COVID-19 who do not require oxygen supplementation

Regeneron Pharmaceuticals, Inc. announced that the European Commission (EC) has approved the casirivimab and imdevimab antibody cocktail, known as REGEN-COV in the U.S. and Ronapreve in the European Union (EU) and other countries. The EC granted marketing authorization for the antibody cocktail for people aged 12 years and older for the treatment of non-hospitalized patients (outpatients) with confirmed COVID-19 who […]

Transplants for alcohol-related liver inflammation surge during pandemic

The increased number of deceased donor liver transplants related to alcoholic hepatitis — up more than 50 percent over predicted numbers — was associated with rising alcohol sales. Registrations for the national organ transplant waiting list related to alcoholic hepatitis as well as the number of deceased donor liver transplants for the inflammatory liver condition rose significantly during the pandemic, […]

Cardiac MRI of myocarditis after COVID-19 vaccination in adolescents

According to ARRS’ American Journal of Roentgenology (AJR), radiologists need to be cognizant of the association between coronavirus disease (COVID-19) mRNA vaccination and myocarditis, as well as the role of cardiac MRI for assessing suspected myocarditis postvaccination. “In this small case series, all patients with myocarditis after COVID-19 vaccination were adolescent males and had a favorable initial clinical course,” explained first author […]

Face Masks return in UK to Combat “worst ever” Covid-19

UK’s prime minister, Boris Johnson, announced the return of face masks in shops and public transport at a Number 10 press conference held on Saturday, November 27, 2021. This comes after the “worst ever” variant of Covid-19 is started to impact the country. The Omicron variant of coronavirus that stems from southern African countries has started to make a presence […]

Research shows mass production can make customised PPE for healthcare workers

Research has demonstrated the feasibility of mass producing customised respiratory protection for healthcare workers with a comfortable close-fitting seal, that is suitable for nearly 90% of face shapes and sizes. Providing adequate filtering PPE for frontline healthcare workers has been a major challenge since the start of the pandemic, and the key issue in providing effective protection is the need for […]

Moderna provides update on timing of U.S. Emergency Use Authorization of its COVID-19 Vaccine for adolescents

Moderna, Inc. provided an update that the FDA has notified the Company that it will require additional time to complete its assessment of Moderna’s Emergency Use Authorization (EUA) request for the use of the Moderna COVID-19 vaccine (mRNA-1273) at the 100 µg dose level in adolescents 12 to 17 years of age. The FDA has informed Moderna that the agency […]

Moderna announces positive top line data from phase II/III study of COVID-19 vaccine in children 6 to 11

-Moderna Inc. announced positive interim data from the Phase II/III study, called the KidCOVE study, of mRNA-1273 , the Company’s vaccine candidate against COVID-19, in children 6 to under 12 years of age. This interim analysis showed a robust neutralizing antibody response after two doses of mRNA-1273 at the 50 µg dose level with a favorable safety profile. Moderna plans […]